Antibiotic prophylaxis in vesicoureteral reflux: A paradigm shift

Por Banerji, J. S., Singh, J. C.
Publicado em 2009

Follow-up after pyeloplasty: How long?

Por Nirmal, T. J., Singh, J. C.
Publicado em 2008

Alfuzosin for chronic pelvic pain syndrome: Another placebo?

Por Nirmal, T. J., Singh, J. C.
Publicado em 2009

Temsirolimus, interferon alfa or both in advanced renal-cell carcinoma: One plus one does not always equal two

Por Grover, S., Singh, J. C., Kekre, N. S.
Publicado em 2007

Endocrine treatment in advanced prostate cancer: When to start?

Por Choudhrie, A. V., Singh, J. C.
Publicado em 2009

Superscan in carcinoma prostate

Por Rajkumar, D., Singh, J. C., Devasia, A.
Publicado em 2008

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development

Por Singh, J C, Jhaveri, K, Esteva, F J
Publicado no Br J Cancer (2014)

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from...

Por Smyth, L. M., Iyengar, N. M., Chen, M. F., Popper, S. M., Patil, S, Wasserheit-Lieblich, C., Argolo, D. F., Singh, J. C., Chandarlapaty, S, Sugarman, S. M., Comen, E. A., Drullinsky, P. R., Traina, T. A., Troso-Sandoval, T, Baselga, J, Norton, L, Hudis, C. A., Dang, C. T.
Publicado no Breast Cancer Res Treat (2016)